CuraGen and TopoTarget Initiate Phase Ib Clinical Trial with PXD101 for Advanced Colorectal Cancer
Proof-of-Concept Trial Evaluating PXD101 Combination Therapy with 5- fluorouracil for Advanced Solid Tumors and Colorectal Cancer
29-Sep-2005 -
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase Ib open-label, multi-center, proof-of-concept clinical trial evaluating PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of advanced solid tumors, including colorectal ...
clinical trials
colorectal cancer
dosing
+4